首页> 外文OA文献 >Expression, pharmacological profile, and functional coupling of A(2B) receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, H-3MRE 2029-F20
【2h】

Expression, pharmacological profile, and functional coupling of A(2B) receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, H-3MRE 2029-F20

机译:使用新型选择性拮抗剂放射性配体H-3 MRE 2029-F20在重组系统和外周血细胞中表达A(2B)受体,表达,药理学特征和功能偶联

摘要

In this study, we compared the pharmacological and biochemical characteristics of A(2B) adenosine receptors in recombinant (hA(2B)HEK293 cells) and native cells (neutrophils, lymphocytes) by using a new potent 8-pyrazole xanthine derivative, [(3)H]N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-dipropyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl-oxy]-acetamide] ([(3)H]MRE 2029-F20), that has high affinity and selectivity for hA(2B) versus hA(1),hA(2A), and hA(3) subtypes. [(3)H]MRE 2029-F20 bound specifically to the hA(2B) receptor stably transfected in human embryonic kidney (HEK) 293 cells with K(D) of 2.8 +/- 0.2 nM and B(max) of 450 +/- 42 fmol/mg of protein. Saturation experiments of [(3)H]MRE 2029-F20 binding in human neutrophils and lymphocytes detected a single high-affinity binding site with K(D) values of 2.4 +/- 0.5 and 2.7 +/- 0.7 nM, respectively, and B(max) values of 79 +/- 10 and 54 +/- 8 fmol/mg of protein, respectively, in agreement with real-time reverse transcription polymerase chain reaction studies showing the presence of A(2B) mRNA. The rank order of potency of typical adenosine ligands with recombinant hA(2B) receptors was consistent with that typically found for interactions with the A(2B) subtype and was also similar in peripheral blood cells. 5'-N-Ethyl-carboxamidoadenosine stimulated cAMP accumulation in both hA(2B)HEK293 and native cells, whereas phospholipase C activation was observed in recombinant receptors and endogenous subtypes expressed in neutrophils but not in lymphocytes. MRE 2029-F20 was revealed to be a potent antagonist in counteracting the agonist effect in both signal transduction pathways. In conclusion, [(3)H]MRE 2029-F20 is a selective and high-affinity radioligand for the hA(2B) adenosine subtype and may be used to quantify A(2B) endogenous receptors. In this work, we demonstrated their presence and functional coupling in neutrophils and lymphocytes that play a role in inflammatory processes in which A(2B) receptors may be involved.
机译:在这项研究中,我们使用新的强效8-吡唑黄嘌呤衍生物比较了重组(hA(2B)HEK293细胞)和天然细胞(嗜中性粒细胞,淋巴细胞)中A(2B)腺苷受体的药理和生化特性[[3 )H] N-苯并[1,3]二氧杂-5-基-2- [5-(1,3-二丙基-2,6-二氧杂-2,3,6,7-四氢-1H-嘌呤-8] -yl)-1-甲基-1H-吡唑-3-基氧基]-乙酰胺]([(3H)] MRE 2029-F20),与hA(1)相比,对hA(2B)具有高亲和力和选择性,hA(2A)和hA(3)子类型。 [(3)H] MRE 2029-F20特异性结合在人类胚胎肾脏(HEK)293细胞中稳定转染的hA(2B)受体,其K(D)为2.8 +/- 0.2 nM,B(max)为450 + /-42 fmol / mg的蛋白质。 [(3)H] MRE 2029-F20结合在人嗜中性粒细胞和淋巴细胞中的饱和实验检测到单个高亲和力结合位点,其K(D)值分别为2.4 +/- 0.5和2.7 +/- 0.7 nM,并且B(max)值分别为79 +/- 10和54 +/- 8 fmol / mg蛋白质,与实时逆转录聚合酶链反应研究一致,表明存在A(2B)mRNA。具有重组hA(2B)受体的典型腺苷配体的效价等级顺序通常与与A(2B)亚型相互作用时发现的等级顺序一致,并且在外周血细胞中也相似。 5'-N-乙基-羧酰胺基腺苷刺激了hA(2B)HEK293和天然细胞中的cAMP积累,而磷脂酶C的激活在嗜中性粒细胞中表达的重组受体和内源性亚型中却未在淋巴细胞中观察到。 MRE 2029-F20被证明是一种有效的拮抗剂,可抵消两种信号转导途径中的激动剂作用。总之,[(3)H] MRE 2029-F20是hA(2B)腺苷亚型的选择性和高亲和力放射性配体,可用于量化A(2B)内源性受体。在这项工作中,我们证明了它们在嗜中性粒细胞和淋巴细胞中的存在和功能偶联,这些细胞在可能涉及A(2B)受体的炎症过程中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号